Posted by Michael Wonder on 05 Dec 2024
Lin BioScience receives US FDA fast track designation for LBS-007
27 November 2024 - A Phase 1/2 trial in patients with relapsed or resistant acute leukaemias is on-going.
Lin BioScience today announced that its lead pipeline, LBS-007, has been granted fast track designation by the US FDA for the treatment of acute myeloid leukaemia.
